A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.

Trial Profile

A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 08 Mar 2016 Results (pooled analysis of this and five other studies (n = 300) assessing olaparib monotherapy in patients with advanced relapsed BRCA1/2 ovarian cancer) published in the Annals of Oncology.
    • 27 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top